A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Phase 1 Study of SLV213 in Healthy Volunteers
Latest Information Update: 29 Jul 2024
At a glance
- Drugs SLV 213 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 26 Jul 2024 Status changed from suspended to discontinued.
- 08 Jul 2024 Status changed from recruiting to suspended.
- 21 Mar 2024 Planned initiation date (estimated date of first participant enrollment) changed from 8 Mar 2024 to 11 Apr 2024.